Journal
SIGNAL TRANSDUCTION AND TARGETED THERAPY
Volume 7, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41392-022-01110-y
Keywords
-
Categories
Funding
- Fundamental Research Funds for the National Natural Science Foundation of China [82003879, 81773889, 82073998]
- Science and Technology Department of Sichuan Province [2022JDRC0045]
- Youth Talent Promotion Project of China Association for Science and Technology [CACM-2020-QNRC1-01]
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC21061]
- [YJ201880]
Ask authors/readers for more resources
Regulated cell death (RCD), also known as programmed cell death (PCD), is a form of cell death that can be controlled by various biomacromolecules, distinct from accidental cell death (ACD). The different subroutines of RCD play crucial roles in tumorigenesis and may lead to the development of potential therapeutic strategies. Targeting the subroutines of RCD with small-molecule compounds has emerged as a promising therapeutic approach and has shown rapid progress in various types of human cancers.
Regulated cell death (RCD), also well-known as programmed cell death (PCD), refers to the form of cell death that can be regulated by a variety of biomacromolecules, which is distinctive from accidental cell death (ACD). Accumulating evidence has revealed that RCD subroutines are the key features of tumorigenesis, which may ultimately lead to the establishment of different potential therapeutic strategies. Hitherto, targeting the subroutines of RCD with pharmacological small-molecule compounds has been emerging as a promising therapeutic avenue, which has rapidly progressed in many types of human cancers. Thus, in this review, we focus on summarizing not only the key apoptotic and autophagy-dependent cell death signaling pathways, but the crucial pathways of other RCD subroutines, including necroptosis, pyroptosis, ferroptosis, parthanatos, entosis, NETosis and lysosome-dependent cell death (LCD) in cancer. Moreover, we further discuss the current situation of several small-molecule compounds targeting the different RCD subroutines to improve cancer treatment, such as single-target, dual or multiple-target small-molecule compounds, drug combinations, and some new emerging therapeutic strategies that would together shed new light on future directions to attack cancer cell vulnerabilities with small-molecule drugs targeting RCD for therapeutic purposes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available